NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free CGON Stock Alerts $41.00 +4.80 (+13.26%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$36.50▼$41.2050-Day Range$33.54▼$47.9352-Week Range$28.55▼$50.23Volume819,590 shsAverage Volume618,633 shsMarket Capitalization$2.73 billionP/E RatioN/ADividend YieldN/APrice Target$61.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial Media Get CG Oncology alerts: Email Address CG Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside50.6% Upside$61.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.19Based on 9 Articles This WeekInsider TradingAcquiring Shares$12.66 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.60) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 starsMedical Sector813th out of 913 stocksBiological Products, Except Diagnostic Industry131st out of 145 stocks 3.4 Analyst's Opinion Consensus RatingCG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CGON. Previous Next 0.0 Dividend Strength Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGON. Previous Next 1.0 News and Social Media Coverage News SentimentCG Oncology has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for CG Oncology this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,662,968.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.60) to ($1.85) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About CG Oncology Stock (NASDAQ:CGON)CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More CGON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGON Stock News HeadlinesApril 26, 2024 | globenewswire.comCG Oncology to Host Virtual Investor Event on Friday, May 3, 2024April 26, 2024 | americanbankingnews.comFY2024 EPS Estimates for CG Oncology, Inc. Lowered by Analyst (NASDAQ:CGON)April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - CGONApril 24, 2024 | globenewswire.comCG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024April 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology Amidst Bladder Cancer Treatment Landscape and BCG ShortageApril 16, 2024 | finance.yahoo.comCG Oncology, Inc. (CGON)April 12, 2024 | msn.com20 Countries with the Most Domestically Listed Companies in the WorldApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 5, 2024 | investing.comCG Oncology Inc (CGON)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology on Strong Clinical Data and Market PotentialApril 1, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Strong Clinical Trial Results and Promising Cretosimogene TherapyMarch 28, 2024 | globenewswire.comCG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingMarch 1, 2024 | seekingalpha.comCGON CG Oncology, Inc.February 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for CG Oncology, Inc. on Promising CG0070 Phase 3 Trials and Unmet Medical NeedFebruary 27, 2024 | finance.yahoo.comCG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder CancerFebruary 20, 2024 | msn.comCantor starts CG Oncology at overweight, cites bladder cancer treatmentFebruary 20, 2024 | realmoney.thestreet.comCG Oncology initiated with neutral view at Goldman Sachs, here's whyFebruary 20, 2024 | realmoney.thestreet.comCG Oncology initiated with bullish view at Morgan Stanley, here's whyFebruary 19, 2024 | cnn.comCG Oncology, Inc.February 15, 2024 | msn.comKairos Pharma sets terms for $6M proposed IPOFebruary 9, 2024 | morningstar.comCG Oncology Inc CGONFebruary 9, 2024 | finance.yahoo.comCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSee More Headlines Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)6/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$61.75 High Stock Price Target$75.00 Low Stock Price Target$42.00 Potential Upside/Downside+50.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.62 Quick Ratio13.62 Sales & Book Value Annual Sales$204,000.00 Price / Sales13,392.53 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-21.13Miscellaneous Outstanding Shares66,636,000Free FloatN/AMarket Cap$2.73 billion OptionableOptionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Arthur Kuan (Age 33)Chairman & CEO Comp: $640.97kMr. Ambaw Bellete M.S. (Age 53)President & COO Comp: $1.06MDr. Vijay Kasturi M.D. (Age 56)Chief Medical Officer Comp: $212.24kMs. Corleen M. Roche (Age 57)CFO & Secretary Ms. Amy SteeleVice President of Finance, Accounting & AdministrationMr. Swapnil Bhargava Ph.D.Chief Technical OfficerMr. Bing KungVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLIVericelNASDAQ:VCELKymera TherapeuticsNASDAQ:KYMRApogee TherapeuticsNASDAQ:APGEArcellxNASDAQ:ACLXView All CompetitorsInsidersHong Fang SongBought 263,157 shares on 1/29/2024Total: $5.00 M ($19.00/share)Decheng Capital Global Life ScBought 400,000 shares on 1/29/2024Total: $7.60 M ($19.00/share)Corleen M RocheBought 2,000 shares on 1/29/2024Total: $38,000.00 ($19.00/share)Vijay KasturiBought 1,315 shares on 1/29/2024Total: $24,985.00 ($19.00/share)View All Insider Transactions CGON Stock Analysis - Frequently Asked Questions Should I buy or sell CG Oncology stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CG Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CGON shares. View CGON analyst ratings or view top-rated stocks. What is CG Oncology's stock price target for 2024? 4 Wall Street analysts have issued 1 year price targets for CG Oncology's shares. Their CGON share price targets range from $42.00 to $75.00. On average, they anticipate the company's share price to reach $61.75 in the next year. This suggests a possible upside of 50.6% from the stock's current price. View analysts price targets for CGON or view top-rated stocks among Wall Street analysts. How have CGON shares performed in 2024? CG Oncology's stock was trading at $37.17 at the beginning of the year. Since then, CGON shares have increased by 10.3% and is now trading at $41.00. View the best growth stocks for 2024 here. When is CG Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our CGON earnings forecast. What ETFs hold CG Oncology's stock? ETFs with the largest weight of CG Oncology (NASDAQ:CGON) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC).Goldman Sachs Future Health Care Equity ETF (GDOC). When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. When did the company's quiet period expire? CG Oncology's quiet period expired on Tuesday, March 5th. CG Oncology had issued 20,000,000 shares in its initial public offering on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGON) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
